Moderna has declined about 30% year to date. The general market downturn surely hurt Moderna shares. It's possible Moderna's recent communications about this potential market has assuaged some of investors' fears.
Market pullbacks can offer a treasure trove of ideas in the form of relative strength.
Pfizer (PFE) and partner BioNTech seek label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in young children under five years.